COMPLETED

Tobacco Treatment Optimization and Preferences During Concurrent Cancer Treatment

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Smoking cessation has been shown to improve the effectiveness and reduce the morbidity of tobacco-related cancer treatments. We will identify effective smoking cessation strategies for patients who are receiving treatment for tobacco-related cancer. In this trial, patients' preferences in smoking cessation therapy will be the principal determinant by providers in developing a three component regimen of pharmaceutical therapy, counseling, and nicotine replacement therapy. This study will identify this cohort's preferences for smoking cessation strategies. We will then examine the impact of utilizing patient preferences upon cessation efficacy by directly comparing cessation success in this study with our recently completed study of the same population using the same tobacco treatments which were randomly assigned.

Official Title

Tobacco Treatment Optimization and Preferences During Concurrent Cancer Treatment

Quick Facts

Study Start:2021-01-12
Study Completion:2026-01-02
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:COMPLETED

Study ID

NCT04634071

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * newly diagnosed or recurrent tobacco related malignancy
  2. * smoked at least 1 cigarette within 4 weeks of study enrollment
  3. * 10-pack year history of cigarette smoking
  4. * smoked at least 1 cigarette within 1 month of cancer diagnosis
  5. * life expectancy greater than 1 year
  1. * allergy to buproprion, varenicline and transdermal medicine
  2. * history of suicide attempt
  3. * hospitalized for psychiatric illness within past 2 years
  4. * history of active or uncontrolled eating disorder
  5. * uncontrolled epilepsy or seizure disorder
  6. * pregnant or lactating
  7. * within 3 months of myocardial infarction
  8. * unstable angina
  9. * uncontrolled hypertension
  10. * serious arrhythmia
  11. * history of taking varenicline or buproprion within one month of enrollment
  12. * concurrent enrollment in tobacco cessation therapy

Contacts and Locations

Principal Investigator

Joseph Valentino, MD
PRINCIPAL_INVESTIGATOR
University of Kentucky

Study Locations (Sites)

Med Center Health
Bowling Green, Kentucky, 42101
United States
University Of Kentucky, Markey Cancer Center
Lexington, Kentucky, 40536
United States
Owensboro Health Mitchell Memorial Cancer Center
Owensboro, Kentucky, 42303
United States

Collaborators and Investigators

Sponsor: Joseph Valentino, MD

  • Joseph Valentino, MD, PRINCIPAL_INVESTIGATOR, University of Kentucky

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2021-01-12
Study Completion Date2026-01-02

Study Record Updates

Study Start Date2021-01-12
Study Completion Date2026-01-02

Terms related to this study

Keywords Provided by Researchers

  • Addiction
  • Cancer Therapy
  • Tobacco
  • nicotine

Additional Relevant MeSH Terms

  • Smoking Cessation
  • Cancer, Treatment-Related